Lycia Therapeutics (NASDAQ:LYCA) Research Coverage Started at Zacks Research

Zacks Research initiated coverage on shares of Lycia Therapeutics (NASDAQ:LYCA – Free Report) in a research report report published on Thursday,Zacks reports. The brokerage issued a hold rating on the stock.

LYCA has been the topic of a number of other research reports. Evercore assumed coverage on Lycia Therapeutics in a research report on Tuesday, November 17th. They set an “outperform” rating and a $43.00 price objective on the stock. Jefferies Financial Group began coverage on Lycia Therapeutics in a report on Tuesday. They issued a “buy” rating and a $50.00 target price for the company. Guggenheim started coverage on Lycia Therapeutics in a research note on Tuesday, November 17th. They set a “buy” rating and a $75.00 target price for the company. TD Cowen began coverage on Lycia Therapeutics in a research note on Tuesday, November 17th. They set a “buy” rating for the company. Finally, Wall Street Zen upgraded Lycia Therapeutics to a “hold” rating in a report on Saturday, October 31st. Five research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $54.00.

View Our Latest Research Report on LYCA

Lycia Therapeutics Stock Up 4.1%

Lycia Therapeutics stock opened at $33.07 on Thursday. Lycia Therapeutics has a 52-week low of $22.19 and a 52-week high of $36.49.

Insider Activity

In other news, major shareholder Venrock Healthcare Capital Par bought 8,305 shares of the stock in a transaction that occurred on Monday, November 2nd. The stock was purchased at an average price of $26.95 per share, for a total transaction of $223,819.75. Following the completion of the purchase, the insider owned 6,858,542 shares in the company, valued at approximately $184,837,706.90. This trade represents a 0.12% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Over the last three months, insiders have acquired 2,078,749 shares of company stock worth $38,526,342.

About Lycia Therapeutics

(Get Free Report)

Lycia Therapeutics is a biotechnology company developing medicines that use its lysosomal targeting chimera (LYTAC) platform to direct disease-related proteins for breakdown inside cells. The approach is designed to address extracellular and cell-surface proteins that may be difficult to target with conventional drug therapies. The company’s work is research and development-focused; it does not have marketed products. Its programs aim to apply targeted protein degradation to conditions including cancer and inflammatory diseases.

Featured Articles

Analyst Recommendations for Lycia Therapeutics (NASDAQ:LYCA)

Receive News & Ratings for Lycia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lycia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.